Premium
Deep venous thrombosis in children with sickle cell disease
Author(s) -
de Oliveira Boechat Tiago,
do Nascimento Emilia Matos,
de Castro Lobo Clarisse Lopes,
Ballas Samir K.
Publication year - 2015
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25431
Subject(s) - medicine , venous thrombosis , thrombosis , incidence (geometry) , medical record , antithrombotic , retrospective cohort study , deep vein , observational study , pediatrics , subclavian vein , disease , pulmonary embolism , surgery , catheter , physics , optics
Background Deep venous thrombosis (DVT) is rare in children compared to adults. Its incidence and risk factors in children are not well known. This study determined these aspects of DVT in children with sickle cell disease (SCD). Procedure A retrospective, observational and descriptive study was performed. Patients born between October 2000 and October 2012 with SCD and registered in HEMORIO, including those who died in HEMORIO, were included in this study. Patients whose medical records were inaccessible, who died in institutions other than HEMORIO, who died with implanted deep venous catheters, and those who were not monitored in HEMORIO for a period of 1 year or more were excluded from the study. Of a total of 1,519 patients, 456 were excluded and 1,063 patients were included in the study. Data were obtained from the computer system and the medical records at HEMORIO. Results Of the 1,063 patients, 2 (0.2%) developed DVT with both cases being related to central venous catheters (CVCs) ( P ‐value <0.001). Of the patients who required CVCs, the prevalence of DVT was 10%. No other variable was clinically or statistically significant with respect to DVT. Conclusion The establishment of CVCs in children with SCD poses a high risk for DVT. If this procedure is necessary, the internal jugular vein should be utilized instead of the subclavian and femoral veins. The identification of associated risk factors may justify antithrombotic prophylaxis. Pediatr Blood Cancer 2015;62:838–841. © 2015 Wiley Periodicals, Inc.